Market Overview

Agilis Biotherapeutics, Intrexon Announce Collaboration


Agilis Biotherapeutics and Intrexon Corporation (NYSE: XON), announced today an Exclusive Channel Collaboration (ECC) to develop DNA-based therapeutics for Friedreich's ataxia (FRDA), a rare genetic neurodegenerative disease.

See full press release

Posted-In: News Guidance Contracts Legal Management Stock Split IPOs Global


Related Articles (XON)

View Comments and Join the Discussion!